Business
Anixa Biosciences Announces Abstract Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)
SAN JOSE, Calif., Oct. 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., Oct. 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced the acceptance of an abstract at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). A poster presentation will include data from ongoing studies utilizing Cchek™, the company's artificial intelligence (AI) driven cancer detection technology. \n\n \nThe SITC meeting is being held November 6 – 10, 2019 in National Harbor, MD. Cutting-edge research will be presented by experts in the field of applied cancer immunotherapy and translational research. The meeting will be attended by both U.S. and international researchers, regulators, and healthcare professionals who are involved in cancer research and clinical care. \nPoster presentation details are as follows:\nTitle: Early detection of breast cancer (BCa) through MDSC and lymphocyte immunophenotyping: from manual gating to pattern recognition neural networks\nAuthors: George A. Dominguez, Ph.D.; John Roop; Alex Polo; Anthony J. Campisi; Dmitry I. Gabrilovich, MD, Ph.D.; Amit Kumar, Ph.D.\nPoster Number: P11\nLocation: Gaylord National Hotel & Convention Center; Poster Hall: Prince George AB\nDate and Time: Friday, November 8, 2019 (12:30 – 2:00 PM ET and 6:30 – 8:00 PM ET)\nTo receive a copy of the presentation, please email your request to [email protected] starting November 10, 2019 and include your name, title, and contact information.\nAbout Cchek™Cchek™ is an early cancer detection technology, which measures a patient's immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient's cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa's orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method with greater affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek™ to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust cancer detection performance of Cchek™ make...